RSSDI Repository, Complications of Diabetes Demonstration RSSDI Repository, Complications of Diabetes Demonstration

Have a Question?

If you have any question you can ask below or enter what you are looking for!

  • Home/
  • Article /
  • A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.

Add to Collection
2013 May Others Fist_Author_Year_PM

Full Author : ['Yang, S J', 'Min, K W', 'Gupta, S K', 'Park, J Y', 'Shivane, V K', 'Pitale, S U', 'Agarwal, P K', 'Sosale, A', 'Gandhi, P', 'Dharmalingam, M', 'Mohan, V', 'Mahesh, U', 'Kim, D M', 'Kim, Y S', 'Kim, J A', 'Kim, P K', 'Baik, S H']
Journal Title : Diabetes, obesity & metabolism
Chapter : Section3
Journal Year : 2013
Cited by : Not Available

AIM: This study was designed to assess the efficacy and safety of the dipeptidyl peptidase IV inhibitor gemigliptin (LC15-0444) 50 mg versus placebo in patients with type 2 diabetes. METHODS: We conducted a 24-week, randomized, double-blind, placebo-contr.....

Keywords : ["multicentre multinational randomize placebocontrolle doubleblind phase trial", "type diabetes", "safety", "patient", "gemigliptin", "evaluate", "efficacy"]